Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cell Therapeutics' Pixantrone Advisory Committee May Include Updated Results Of Pivotal Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA declined to give the NME for recurring, aggressive non-Hodgkin's lymphoma priority review, but the firm hopes that progression free survival data and safety argument will be compelling to ODAC.

You may also be interested in...



Cell Therapeutics' Pixuvri Could Be Stopped By Early Trial Termination

Advisory committee will consider whether the results for the non-Hodgkin's lymphoma treatment's Phase III trial, which suffered an unplanned early halt, are sufficient.

Cell Therapeutics' Pixuvri Could Be Stopped By Early Trial Termination

Advisory committee will consider whether the results for the non-Hodgkin's lymphoma treatment's Phase III trial, which suffered an unplanned early halt, are sufficient.

Anticipating Pixantrone Approval, Cell Therapeutics Adopts A "Poison Pill" Plan

The shareholder rights plan includes a provision that is intended to forestall a hostile takeover bid.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS068890

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel